Table 4.

Univariate and multivariate Cox regression analysis for DSS in a series of 202 OPSCC patients and separately for those with either a HPV-positive tumor or a HPV-negative tumor

	Univariate analysis			Multivariate analysis			Multivariate analysis			Multivariate analysis
	All patients			All patients			HPV-positive patients			HPV-negative patients
	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
Sex
Male vs. female	2.2	1.0–4.9	0.054	2.2	1.0–5.0	0.061	1.1	0.3–4.2	0.874	3.4	1.1–10.4	0.029
Smoking			0.038
Earlier vs. never	1.7	0.5–6.0	0.439
Currently vs. never	3.3	1.0–10.7	0.048
T class			0.060			0.063			0.235			0.266
T2 vs. T1	3.0	0.7–5.3	0.178	2.0	0.7–5.8	0.174	2.3	0.2–21.9	0.463	2.3	0.7–7.6	0.188
T3 vs. T1	1.8	0.6–5.3	0.284	1.2	0.4–3.6	0.747	2.2	0.2–22.9	0.511	1.0	0.3–3.8	0.980
T4 vs. T1	3.6	1.3–10.0	0.013	3.1	1.1–8.9	0.031	5.5	0.6–48.5	0.122	2.4	0.7–8.4	0.169
N class
N2–3 vs. N0–1	2.1	1.0–4.2	0.037	3.6	1.7–7.5	0.001	4.0	0.8–19.2	0.084	3.4	1.4–8.2	0.007
TLR 5			0.005			0.228			0.033			0.761
1 vs. 0	1.9	0.7–5.5	0.218	2.0	0.7–5.7	0.169	3.6	0.7–19.3	0.129	2.1	0.4–9.5	0.353
2 vs. 0	2.6	1.1–6.3	0.027	1.7	0.7–4.2	0.280	2.4	0.6–10.2	0.240	1.4	0.4–5.2	0.594
3 vs. 0	4.9	2.0–12.2	0.001	2.8	1.0–7.8	0.051	11.7	2.1–63.6	0.005	1.8	0.4–7.8	0.405
TLR 7			0.002			0.085			0.001			0.739
1 vs. 3	4.4	1.9–10.0	<0.001	3.2	1.1–9.0	0.027	20.8	4.0–107.1	<0.001	1.6	0.4–6.0	0.471
2 vs. 3	2.4	1.1–5.5	0.031	2.1	0.9–5.2	0.089	2.4	0.7–8.2	0.158	1.3	0.4–4.5	0.693
TLR 9			0.584
0 vs. 3	0.0	–	0.975
1 vs. 3	0.5	0.2–1.3	0.165
2 vs. 3	0.8	0.5–1.5	0.567
HPV
HPV− vs. HPV+	2.2	1.2–4.0	0.007	1.6	0.8–3.3	0.181
Treatment
(C)RT ± Sx vs. Sx ± (C)RT	1.0	0.6–1.8	0.975